References

russjcardiol

Российский кардиологический журнал

Russian Journal of Cardiology

1560-40712618-7620

«SILICEA-POLIGRAF» LLC

10.15829/1560-4071-2021-4699

russjcardiol-4699

Research Article

ОБЗОРЫ

REVIEW

Влияние базовой терапии на частоту повторных госпитализаций по поводу декомпенсации сердечной недостаточности: возможности и ограничения в современной клинической практике

Influence of standard heart failure therapy on readmission rate: opportunities and limitations in modern clinical practice

https://orcid.org/0000-0002-8505-1848

Гиляревский

С. Р.

Gilyarevsky

S. R.

Доктор медицинских наук, профессор, профессор, профессор кафедры клинической фармакологии и терапии

Москва

Moscow

sgilarevsky@rambler.ru

Российская медицинская академия непрерывного профессионального образования Минздрава РоссииРоссияRussian Medical Academy of Continuous Professional EducationRussian Federation

2021

27092021

261046994699

2021

Гиляревский С.Р.

Gilyarevsky S.R.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://russjcardiol.elpub.ru/jour/article/view/4699

В настоящем обзоре рассматривается клиническое и эпидемиологическое значение госпитализаций по поводу декомпенсации сердечной недостаточности, а также особенности использования указанных событий в качестве показателя эффективности проводимой терапии. Приведены данные о частоте применения препаратов, снижающих риск госпитализаций, в рандомизированных клинических исследованиях и в реальной практике. Обсуждаются причины недостаточно частого назначения препаратов для лечения сердечной недостаточности со сниженной фракцией выброса и использования их в недостаточно высоких дозах, к которым относятся терапевтическая инертность и физиологические ограничения и необходимость внедрения в клиническую практику препаратов с альтернативными механизмами действия.

This review considers the clinical and epidemiological significance of hospitalizations for decompensated heart failure, as well as using it as an indicator of therapy effectiveness. The data on the frequency of using medications that reduce the hospitalization risk in randomized clinical trials and in real practice are presented. The reasons for inadequate prescription of drugs for the treatment of heart failure with reduced ejection fraction and their use in insufficient doses, which include therapeutic inertness and physiological limitations, as well as the need to introduce drugs with alternative mechanisms of action into clinical practice, are iscussed.

сердечная недостаточностьлекарственная терапияэпизод декомпенсации

heart failuremedication therapyepisode of decompensation

Публикация подготовлена при поддержке компании АО “БАЙЕР”, PP-VER-RU-0005-1.

This publication was supported by Bayer (PP-VERRU-0005-1).

References1

Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325(21):1468-75. doi:10.1056/NEJM199111213252103.

Packer M, Pitt B, Rouleau JL, et al. Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years. JACC Heart Fail. 2017;5(6):399-407. doi:10.1016/j.jchf.2017.03.003.

Fiuzat M, Lowy N, Stockbridge N, et al. Endpoints in Heart Failure Drug Development: History and Future. JACC Heart Fail. 2020;8(6):429-40. doi:10.1016/j.jchf.2019.12.011.

Goenka L, George M, Selvarajan S. End points in heart failure-are we doing it right? Eur J Clin Pharmacol. 2017;73(6):651-9. doi:10.1007/s00228-017-2228-0.

Solomon SD, Dobson J, Pocock S, et al; Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116:1482-7. doi:10.1161/CIRCULATIONAHA.107.696906.

Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154:260-6. doi:10.1016/j.ahj.2007.01.041.

Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2019;74(15):1966-2011. doi:10.1016/j.jacc.2019.08.001. Erratum in: J Am Coll Cardiol. 2020;75(1):132.

Collins SP, Pang PS, Lindsell CJ, et al. International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes. Eur J Heart Fail. 2010;12:1253-60. doi:10.1093/eurjhf/hfq133.

Zannad F, Garcia AA, Anker SD, et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail. 2013;15(10):1082-94. doi:10.1093/eurjhf/hft095.

Blair JE, Zannad F, Konstam MA, et al; EVEREST Investigators. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol. 2008;52(20):1640-8. doi:10.1016/j.jacc.2008.07.056.

Rogers JK, Jhund PS, Perez AC, et al. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC Heart Fail. 2014;2(3):289-97. doi:10.1016/j.jchf.2013.12.007.

Ponikowski P, Kirwan BA, Anker SD, et al; AFFIRM-AHF investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895-904. doi:10.1016/S0140-6736(20)32339-4.

Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-24. doi:10.1056/NEJMoa2022190.

Fonarow GC, Abraham WT, Albert NM, et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med. 2007;167:1493-502. doi:10.1001/archinte.167.14.1493.

Maggioni AP, Dahlstrom U, Filippatos G, et al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2010;12:1076-84. doi:10.1093/eurjhf/hfq154.

Bueno H, Ross JS, Wang Y, et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA. 2010;303:2141-7. doi:10.1001/jama.2010.748.

Adams KFJr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-16. doi:10.1016/j.ahj.2004.08.005.

Follath F, Yilmaz MB, Delgado JF, et al. Clinical presentation, management and out- comes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med. 2011;37:619-26. doi:10.1007/s00134-010-2113-0.

Eapen Z, Reed S, Yanhong L, et al. Do countries or hospitals with longer stays have lower readmission rates? Findings from the ASCEND-HF trial. Circ Heart Fail. 2013;6(4):727-32. doi:10.1161/CIRCHEARTFAILURE.112.000265.

Sato N, Kajimoto K, Asai K, et al. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. Am Heart J. 2010;159:949-55. doi:10.1016/j.ahj.2010.03.019.

Fonarow GC, Abraham WT, Albert NM, et al. Day of admission and clinical outcomes for patients hospitalized for heart failure: findings from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Circ Heart Fail. 2008;1(1):50-7. doi:10.1161/CIRCHEARTFAILURE.107.748376.

Bhatt DL, Szarek M, Steg PG, et al; SOLOIST-WHF Trial Investigators. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384(2):117-28. doi:10.1056/NEJMoa2030183.

Anker SD, McMurray JJ. Time to move on from ‘time-to-first’: should all events be included in the analysis of clinical trials? Eur Heart J. 2012;33:2764-5. doi:10.1093/eurheartj/ehs277.

Rogers JK, McMurray JJ, Pocock SJ, et al. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation. 2012;126(19):2317-23. doi:10.1161/CIRCULATIONAHA.112.110536.

Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2012;33:176-2. doi:10.1093/eurheartj/ehr352.

Rogers JK, Pocock SJ, McMurray JJ, et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur J Heart Fail. 2014;16(1):33-40. doi:10.1002/ejhf.29. Erratum in: Eur J Heart Fail. 2014;16(5):592.

Borer JS, Böhm M, Ford I, et al; SHIFT Investigators. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J. 2012;33(22):2813-20. doi:10.1093/eurheartj/ehs259.

Allen LA, Hernandez AF, O'Connor CM, Felker GM. End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol. 2009;53(24):2248-58. doi:10.1016/j.jacc.2008.12.079.

Ariti CA, Cleland JG, Pocock SJ, et al. Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J. 2011;162(5):900-6. doi:10.1016/j.ahj.2011.08.003.

Khan MS, Sreenivasan J, Lateef N, et al. Trends in 30- and 90-Day Readmission Rates for Heart Failure. Circ Heart Fail. 2021;14(4):e008335. doi:10.1161/CIRCHEARTFAILURE.121.008335.

Butler J, Yang M, Manzi MA, et al. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019;73(8):935-44. doi:10.1016/j.jacc.2018.11.049.

Butt JH, Fosbøl EL, Gerds TA, et al. Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort. Eur J Heart Fail. 2020;22(10):1777-85. doi:10.1002/ejhf.1800.

Фомин И.В. Хроническая сердечная недостаточность в российской федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;(8):7-13. doi:10.15829/1560-4071-2016-8-7-13.

Fomin IV. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016;(8):7-13. (In Russ.) doi:10.15829/1560-4071-2016-8-7-13.

Greene SJ, Fonarow GC, Butler J. Risk Profiles in Heart Failure: Baseline, Residual, Worsening, and Advanced Heart Failure Risk. Circ Heart Fail. 2020;13(6):e007132. doi:10.1161/CIRCHEARTFAILURE.120.007132.

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-7. doi:10.1016/S0140-6736(99)04440-2.

CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-35. doi:10.1056/NEJM198706043162301.

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13. doi:10.1016/S0140-6736(98)11181-9.

Packer M, Coats AJ, Fowler MB, et al; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651-8. doi:10.1056/NEJM200105313442201.

Zannad F, McMurray JJ, Krum H, et al; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. doi:10.1056/NEJMoa1009492.

McMurray JJ, Packer M, Desai AS, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077.

McMurray JJV, Solomon SD, Inzucchi SE, et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303.

Verhestraeten C, Heggermont WA, Maris M. Clinical inertia in the treatment of heart failure: a major issue to tackle. Heart Fail Rev. 2020. Ahead of print. doi:10.1007/s10741-020-09979-z.

Crespo-Leiro MG, Segovia-Cubero J, González-Costello J, et al; project research team. Adherence to the ESC Heart Failure Treatment Guidelines in Spain: ESC Heart Failure Long-term Registry. Rev Esp Cardiol (Engl Ed). 2015;68(9):785-93. doi:10.1016/j.rec.2015.03.008.

Komajda M, Anker SD, Cowie MR, et al. Physicians' adher- ence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016;18(5):514-22. doi:10.1002/ejhf.510.

Greene SJ, Butler J, Albert NM, et al. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018;72(4):351-66. doi:10.1016/j.jacc.2018.04.070.

Brunner-La Rocca HP, Linssen GC, Smeele FJ, et al., Investigators C-H. Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF Registry. JACC Heart Fail. 2019;7(1):13-21. doi:10.1016/j.jchf.2018.10.010.

Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010;122(6):585-96. doi:10.1161/CIRCULATIONAHA.109.934471.

Linssen GCM, Veenis JF, Brunner-La Rocca HP, et al; CHECK-HF investigators. Differences in guideline-recommended heart failure medication between Dutch heart failure clinics: an analysis of the CHECK-HF registry. Neth Heart J. 2020;28(6):334-44. doi:10.1007/s12471-020-01421-1.

Maggioni AP, Dahlström U, Filippatos G, et al.; Heart Failure Association of the European Society of Cardiology (HFA). EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15(7):808-17. doi:10.1093/eurjhf/hft050.

Epstein M, Reaven NL, Funk SE, et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 2015;21(suppl 11):S212-20.

Savarese G, Xu H, Trevisan M, et al. Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. JACC Heart Fail. 2019;7(1):65-76. doi:10.1016/j.jchf.2018.10.003.

Rossignol P, Ménard J, Fay R, et al. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol. 2011;58(19):1958-66. doi:10.1016/j.jacc.2011.04.049.

Nordberg Backelin C, Fu M, Ljungman C. Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting. ESC Heart Fail. 2020;7(3):1049-55. doi:10.1002/ehf2.12644.

O'Connor PJ, Sperl-Hillen JM, Johnson PE, et al., editors. Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology). Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Feb.

Aujoulat I, Jacquemin P, Rietzschel E, et al. Factors associated with clinical inertia: an integrative review. Adv Med Educ Pract 2014;5:141-7. doi:10.2147/AMEP.S59022.

Jarjour M, Henri C, de Denus S, et al. Care Gaps in Adherence to Heart Failure Guidelines: Clinical Inertia or Physiological Limitations? JACC Heart Fail. 2020;8(9):725-38. doi:10.1016/j.jchf.2020.04.019.

Honigberg MC, Vardeny O, Vaduganathan M. Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure. Circ Heart Fail. 2020;13(2):e006623. doi:10.1161/CIRCHEARTFAILURE.119.006623.

The authors declare that there are no conflicts of interest present.